This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Agus, D. B. Articles by Scher, H. I. Search for Related Content PubMed PubMed Citation Articles by Agus, D. B. Articles by Scher, H. I.

Positron Emission Tomography of a Human Prostate Cancer Xenograft: Association of Changes in Deoxyglucose Accumulation with Other Measures of Outcome following Androgen Withdrawal¹

Hematologic Oncology Division, Department of Medicine and Sloan-Kettering Institute [D. B. A., D. W. G.]; Genitourinary Oncology Service, Department of Medicine [H. I. S.]; Department of Medical Physics [G. S., A. B.]; and Department of Pathology and Sloan-Kettering Institute [C. C-C.], Memorial Sloan-Kettering Cancer Center, New York, New York 10021

The current means of assessing response in prostate cancer are imprecise because changes in tumor size are often slow and difficult to document, and alterations in serum prostate-specific antigen (PSA) levels do not always correlate with clinical outcomes. Using the CWR22 human prostate cancer xenograft model, serial changes in prostate tumor metabolism were assessed after androgen withdrawal by [³H]deoxyglucose (DOG) accumulation in the tumors and noninvasively using positron emission tomography (PET) with 2-[¹⁸F]-fluoro-2-deoxy-D-glucose as a radiotracer. A significant decrease in [³H]DOG accumulation was observed at 48 h after androgen withdrawal [62% of preandrogen withdrawal value (95% confidence interval: 0.59, 0.65)], reaching a maximum decline at day 10 [38% of preandrogen withdrawal value (95% confidence interval: 0.37, 0.40)]. Using PET, parallel changes in tumor metabolism were demonstrated and preceded changes in tumor volume and marked declines in serum PSA. DOG accumulation returned to near baseline upon reintroduction of androgen. The decrease in DOG accumulation was associated with a decline in the proportion of tumor cells in active cell cycle from >60% to <5% at 7–10 days after androgen withdrawal. No increase in the proportion of tumor cells undergoing apoptosis was observed during this time period, implying an arrest in a G₀/early G₁ state. DOG accumulation in tumor cells, measured directly and by PET, correlated with androgen changes in the host. The results suggest that serial monitoring of DOG accumulation using PET scanning may be useful as an early indicator of treatment efficacy and other outcome measures in prostate cancer.

¹ This study was supported in part by NIH Grants R01CA30388, R01HL42107, P30CA08748 (to D. B. A. and D. W. G.), CA05826 (to H. I. S.), and CADR47650 (to C. C-C.); the Hascoe and PepsiCo Funds; and CapCURE (to H. I. S., D. B. A., and D. W. G.). D. B. A. is supported by a Physician's Research Training Award from the American Cancer Society.

² To whom requests for reprints should be addressed, at Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Box 560, New York, NY 10021. Phone: (212) 639-2820; Fax: (212) 772-8550; E-mail: d-agus@ski.mskcc.org.

Received 3/11/98. Accepted 5/18/98.

This article has been cited by other articles:

				K. B. Contractor and E. O. Aboagye Monitoring Predominantly Cytostatic Treatment Response with 18F-FDG PET J. Nucl. Med., May 1, 2009; 50(Suppl_1): 97S - 105S. [Abstract] [Full Text] [PDF]

				A. L. Vavere, S. J. Kridel, F. B. Wheeler, and J. S. Lewis 1-11C-Acetate as a PET Radiopharmaceutical for Imaging Fatty Acid Synthase Expression in Prostate Cancer J. Nucl. Med., February 1, 2008; 49(2): 327 - 334. [Abstract] [Full Text] [PDF]

				D. Feltquate, L. Nordquist, C. Eicher, M. Morris, O. Smaletz, S. Slovin, T. Curley, A. Wilton, M. Fleisher, G. Heller, et al. Rapid Androgen Cycling as Treatment for Patients with Prostate Cancer Clin. Cancer Res., December 15, 2006; 12(24): 7414 - 7421. [Abstract] [Full Text] [PDF]

				H. Schoder, K. Herrmann, M. Gonen, H. Hricak, S. Eberhard, P. Scardino, H. I. Scher, and S. M. Larson 2-[18F]Fluoro-2-Deoxyglucose Positron Emission Tomography for the Detection of Disease in Patients with Prostate-Specific Antigen Relapse after Radical Prostatectomy Clin. Cancer Res., July 1, 2005; 11(13): 4761 - 4769. [Abstract] [Full Text] [PDF]

				P. B. Zanzonico, R. Finn, K. S. Pentlow, Y. Erdi, B. Beattie, T. Akhurst, O. Squire, M. Morris, H. Scher, T. McCarthy, et al. PET-Based Radiation Dosimetry in Man of 18F-Fluorodihydrotestosterone, a New Radiotracer for Imaging Prostate Cancer J. Nucl. Med., November 1, 2004; 45(11): 1966 - 1971. [Abstract] [Full Text] [PDF]

				H. I. Scher, M. Eisenberger, A. V. D'Amico, S. Halabi, E. J. Small, M. Morris, M. W. Kattan, M. Roach, P. Kantoff, K. J. Pienta, et al. Eligibility and Outcomes Reporting Guidelines for Clinical Trials for Patients in the State of a Rising Prostate-Specific Antigen: Recommendations From the Prostate-Specific Antigen Working Group J. Clin. Oncol., February 1, 2004; 22(3): 537 - 556. [Abstract] [Full Text] [PDF]

				J. P. Dyke, K. L. Zakian, W. M. Spees, C. Matei, Y. Chen, X. Mao, D. C. Shungu, and J. A. Koutcher Metabolic Response of the CWR22 Prostate Tumor Xenograft after 20 Gy of Radiation Studied by 1H Spectroscopic Imaging Clin. Cancer Res., October 1, 2003; 9(12): 4529 - 4536. [Abstract] [Full Text] [PDF]

				W. Arap, W. Haedicke, M. Bernasconi, R. Kain, D. Rajotte, S. Krajewski, H. M. Ellerby, D. E. Bredesen, R. Pasqualini, and E. Ruoslahti Targeting the prostate for destruction through a vascular address PNAS, February 5, 2002; 99(3): 1527 - 1531. [Abstract] [Full Text] [PDF]

				R. Nunez, H. A. Macapinlac, H. W.D. Yeung, T. Akhurst, S. Cai, I. Osman, M. Gonen, E. Riedel, H. I. Scher, and S. M. Larson Combined 18F-FDG and 11C-Methionine PET Scans in Patients with Newly Progressive Metastatic Prostate Cancer J. Nucl. Med., January 1, 2002; 43(1): 46 - 55. [Abstract] [Full Text] [PDF]

				B. A. Usmani, R. Shen, M. Janeczko, C. N. Papandreou, W.-H. Lee, W. G. Nelson, J. B. Nelson, and D. M. Nanus Methylation of the Neutral Endopeptidase Gene Promoter in Human Prostate Cancers Clin. Cancer Res., May 1, 2000; 6(5): 1664 - 1670. [Abstract] [Full Text] [PDF]

				M. Drobnjak, I. Osman, H. I. Scher, M. Fazzari, and C. Cordon-Cardo Overexpression of Cyclin D1 Is Associated with Metastatic Prostate Cancer to Bone Clin. Cancer Res., May 1, 2000; 6(5): 1891 - 1895. [Abstract] [Full Text] [PDF]

				D. B. Agus, C. Cordon-Cardo, W. Fox, M. Drobnjak, A. Koff, D. W. Golde, and H. I. Scher Prostate Cancer Cell Cycle Regulators: Response to Androgen Withdrawal and Development of Androgen Independence J Natl Cancer Inst, November 3, 1999; 91(21): 1869 - 1876. [Abstract] [Full Text] [PDF]